Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Shaw

Showing results (71-80 of 132) with videos related to

Pageof 14
Sort By:
Blood|October 24, 2002
Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remissionFranco Locatelli, Myriam Labopin, Juan Ortega, et al.
British Journal of Clinical Pharmacology|September 16, 2010
Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantationLihua Zeng, Elaine Y L Blair, Christa E Nath, et al.
Vaccine|August 13, 2019
Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised childrenC Raina MacIntyre, Peter J Shaw, Fiona E Mackie, et al.
Blood|June 17, 2009
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313Michael A Pulsipher, Kenneth M Boucher, Donna Wall, et al.
British Journal of Clinical Pharmacology|February 17, 2016
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantationChrista E Nath, Judith Trotman, Campbell Tiley, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 28, 2021
Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic studyKhalil Ben Hassine, Tiago Nava, Yves Théoret, et al.
British Journal of Clinical Pharmacology|June 25, 2010
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapyChrista E Nath, Peter J Shaw, Judith Trotman, et al.
Journal of Pediatric Hematology/Oncology|December 4, 2020
Hematopoietic Stem Cell Transplantation for Hepatitis-associated Aplastic Anemia Following Liver Transplantation for Nonviral Hepatitis: A Retrospective Analysis and a Review of the Literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow TransplantationAlexander B Mohseny, Dirk-Jan A Eikema, Benedicte Neven, et al.
Clinical Pharmacokinetics|March 30, 2012
Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosingImke H Bartelink, Jaap J Boelens, Robbert G M Bredius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphomaMaher K Gandhi, Eleanore Lambley, Jacqueline Burrows, et al.
Pageof 14

Showing results (71-80 of 132) with videos related to

Sort By:
Pageof 14
Blood|October 24, 2002
Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remissionFranco Locatelli, Myriam Labopin, Juan Ortega, et al.
British Journal of Clinical Pharmacology|September 16, 2010
Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantationLihua Zeng, Elaine Y L Blair, Christa E Nath, et al.
Vaccine|August 13, 2019
Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised childrenC Raina MacIntyre, Peter J Shaw, Fiona E Mackie, et al.
Blood|June 17, 2009
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313Michael A Pulsipher, Kenneth M Boucher, Donna Wall, et al.
British Journal of Clinical Pharmacology|February 17, 2016
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantationChrista E Nath, Judith Trotman, Campbell Tiley, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 28, 2021
Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic studyKhalil Ben Hassine, Tiago Nava, Yves Théoret, et al.
British Journal of Clinical Pharmacology|June 25, 2010
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapyChrista E Nath, Peter J Shaw, Judith Trotman, et al.
Journal of Pediatric Hematology/Oncology|December 4, 2020
Hematopoietic Stem Cell Transplantation for Hepatitis-associated Aplastic Anemia Following Liver Transplantation for Nonviral Hepatitis: A Retrospective Analysis and a Review of the Literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow TransplantationAlexander B Mohseny, Dirk-Jan A Eikema, Benedicte Neven, et al.
Clinical Pharmacokinetics|March 30, 2012
Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosingImke H Bartelink, Jaap J Boelens, Robbert G M Bredius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphomaMaher K Gandhi, Eleanore Lambley, Jacqueline Burrows, et al.
Pageof 14